On February 16 the FDA announced the approval of TIL therapy or AMTAGVIâ„¢ the first cellular therapy indicated for the treatment of adult patients with cutaneous (skin) me...

Guest blog post by Nick Doble, ocular melanoma caregiver and MRF supporter: “Being a caregiver is hard, and it’s not something you sign up for. It’s full of compl...

For the past two years, the Miller Family, along with their circle of friends and the unwavering support of their community, embarked on a remarkable journey to shed light ...

First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration with Complete BLA Submission on Track for Fourth Quarter 2022 On August 25, Iovance Biothe...

The MRF is proud to join our fellow members of the National Council on Skin Cancer Prevention (NCSCP) in urging the U.S. Food and Drug Administration (FDA) to finalize prop...

On March 15, the U.S. Food and Drug Administration (FDA) granted Iovance Biotherapeutics, Inc. an Investigational New Drug Application (IND) for IOV-4001, its first geneti...

On January 26, 2022, the U.S. Food and Drug Administration announced the approval of KIMMTRAK (tebentafusp-tebn), the first and only FDA-approved treatment for metastatic u...

Guest blog post by Keith T. Flaherty, MD, Associate Professor of Medicine at Harvard Medical School, Director of Developmental Therapeutics at Massachusetts General Hospita...

For our 25th anniversary, we share a guest blog from Vito Rebecca, PhD from Johns Hopkins University Bloomberg School of Public Health: As a scientist, a translational rese...

For our 25th anniversary, we share a guest blog from Richard D. Carvajal, MD from Columbia University Herbert Irving Comprehensive Cancer Center and recipient of the CURE O...

WASHINGTON, DC – The Melanoma Research Foundation (MRF) recently signed– on to a letter from the National Council of Skin Cancer Prevention (NCSCP) urging ...

WASHINGTON, DC – The U.S. Food and Drug Administration (FDA) has recently granted orphan drug designation for the treatment of mucosal melanoma to Alkermes’ investi...